Structure-based design that H-bonds the L2-loop residue S531 — unique to HDAC6 among all isoforms — yields 20b, a 3.4 nM HDAC6 inhibitor with 224-fold selectivity that kills A549 lung-cancer cells via autophagy and modulates stress-granule / liquid-liquid phase separation.
Read article →
Novartis/MMV used phenotypic screening with deliberate mode-of-action de-risking to find IWY357, a pyrazine-2-carboxamide with single-digit-nanomolar dual Pf/Pv activity, a high resistance barrier, and PK supporting a single-oral-dose cure in a humanized mouse model — now in Phase 1.
Read article →
GSK built a noncovalent, ultrahigh-affinity (SPR pKd 10.9) inhibitor of the KEAP1–NRF2 protein–protein interaction by pre-organizing the free ligand into its bioactive conformation — GSK3227634, the first NRF2 activator with lung target engagement and efficacy by direct (inhaled) delivery for COPD.
Read article →
Amgen used a property-biased covalent DNA-encoded library — engineered for CNS-friendly space (HBD=0, low PSA) up front — to discover AM-8719, a brain-penetrant, orally efficacious KRAS G12C inhibitor with ~200-fold improved potency and K(p,uu) ten-fold above sotorasib/adagrasib.
Read article →
A transparent HTE/DoE study turning a Pd-catalyzed monoarylation of ammonia (the abemaciclib amine fragment) into a nickel-catalyzed one — with a transferable three-descriptor SAR model for Ni ligands and an honest look at the scale-up isolation problem.
Read article →
How an electrophile-first/ligand-first strategy converted weak reversible SHP2 latch-site ligands into the first potent (15 nM) covalent allosteric inhibitors.
Read article →
Compiled: 2026-10-22 · Trigger event: FDA approval, 2026-09-25 Innovator: Mirum Pharmaceuticals, Inc. (Foster City, CA) – NDA holder and US commercial lead. ‘Licensed from: Incyte Corporation, Wilmington, DE’ and ‘ATEBRIOZ is a trademark of Incyte’ per label back page. Incyte developed the molecule…
Read article →
Compiled: 2026-10-22 · Trigger event: FDA approval, 2026-09-25 Innovator: AbbVie Inc., 1 N. Waukegan Road, North Chicago, IL 60064 (Marketed by AbbVie Inc.; JUVMO is a trademark of Cerevel Therapeutics, LLC, an AbbVie company). Chain of origin: DISCOVERED AT PFIZER (Brodney, Davoren, Gray…
Read article →
Compiled: 2026-10-22 · Trigger event: FDA approval, 2026-09-04 Innovator: AstraZeneca Pharmaceuticals LP (sponsor of record: ASTRAZENECA). Camizestrant (AZD9833) was discovered in-house at AstraZeneca (Scott et al., J. Med. Chem. 2020) – a fully internal asset, no in-licensing. Status:…
Read article →
Mechanism: Lirafugratinib (RLY-4008) is a highly selective, IRREVERSIBLE (covalent) small-molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2). A methacrylamide (2-methylprop-2-enamide) Michael-acceptor warhead covalently engages Cys491 at the tip of the FGFR2 phosphate-binding (P)-loop (homologous Cys488 in FGFR1). Selectivity…
Read article →